We are Sorry, This Page doesn't Exist
Lexicon Pharmaceuticals Inc. (LXRX) CEO Lonnel Coats on Q2 2019 Results - Earnings Call Transcript
Lexicon Pharmaceuticals Inc. (LXRX) CEO Lonnel Coats on Q2 2019 Results - Earnings Call Transcript.....»»
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2019 Results - Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2019 Results - Earnings Call Transcript.....»»
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2018 Results - Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2018 Results - Earnings Call Transcript.....»»
Lexicon Pharmaceuticals" (LXRX) CEO Lonnel Coats on Q1 2018 Results - Earnings Call Transcript
Lexicon Pharmaceuticals" (LXRX) CEO Lonnel Coats on Q1 2018 Results - Earnings Call Transcript.....»»
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2018 Results - Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2018 Results - Earnings Call Transcript.....»»
Lexicon Pharmaceuticals: Q1 Earnings Insights
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 200.00% over the past year to ($0.63), which beat the estimate of ($0.69). Revenue of $7.....»»
Lexicon Pharmaceuticals: Q1 Earnings Insights
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 200.00% over the past year to ($0.63), which beat the estimate of ($0.69). read more.....»»
Why Lexicon Pharma Shares Are Moving Lower
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. 0 read more.....»»
Mirum Pharmaceuticals Inc (MIRM) President and CEO Christopher Peetz Bought $99,951 of Shares
Related Stocks: MIRM,.....»»
Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi
Lexicon Pharmaceuticals (NASDAQ: LXRX) shares plummeted after the company received a written notice from Sanofi (NASDAQ: SNY) terminating the agreement for the development and commercialization of the company's Diabe read more.....»»
Citius Pharmaceuticals Inc (CTXR) President and CEO Myron Z Holubiak Bought $200,648 of Shares
Related Stocks: CTXR,.....»»
Amneal Pharmaceuticals Inc (AMRX) President and CEO Robert A Stewart Bought $202,640 of Shares
Related Stocks: AMRX,.....»»
Intercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Bought $499,968 of Shares
Related Stocks: ICPT,.....»»
Most Admired For-Profit CEO: Lonnel Coats
Lexicon Pharmaceuticals' Lonnel Coats has been named a Most Admired CEO by the Houston Business Journal......»»
Here"s Why Lexicon Pharmaceuticals Lost 28.8% in January
What happened Shares of Lexicon Pharmaceuticals NASDAQ LXRX fell nearly 29 last month according to data provided by S amp P Global Market Intelligence The company announced that its lead drug candidate Zynquista didn t muster a majority of support from an.....»»
Lexicon Pharmaceuticals Stock Is Estimated To Be Significantly Overvalued
Related Stocks: LXRX,.....»»
Banc Of California Inc (BANC) PRESIDENT AND CEO Jared M Wolff Bought $99,400 of Shares
Related Stocks: BANC,.....»»
Zentalis Pharmaceuticals Inc (ZNTL) President & CEO Anthony Y Sun Sold $2.8 million of Shares
Related Stocks: ZNTL,.....»»
Syros Pharmaceuticals director Mark Alles bought 10K shares of company stock
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
THE WOODLANDS, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), to.....»»